Was ESG a stock market vaccine during COVID-19?

Julia Asri Meigh, Head of ESG and Macro Research (New York)

Post feature

We summarise findings from a recent academic work that investigated whether ESG investing offered funds any resilience during the COVID-19 crisis.


In this Literature Review, we discuss the August 2020 paper titled

Request a Neudata trial

We'd like to know a bit more about you and your business, so we can deal with your request efficiently.
We take your privacy seriously and handle your personal data in line with our privacy statement.

We use your email address as part of allowing you access to your account and in order to provide you details with our products that might be of interest to you